Speaker:

Albrecht Stenzinger, M.D.

Moderator:

Jonathan Nowak, M.D.,Ph.D.

 

This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA. If you would like continuing education credit for the webinar, click on the links in the table below to access the webinar + CME/CMLE or webinar + SAM.


Description: Approaches to calculating, reporting, and interpreting Tumor Mutational Burden (TMB) testing will be discussed in this second of two updates on the broader use of TMB as a potentially prognostic and predictive tool in clinical care. Dr. Stenzinger will provide an overview of how large-scale efforts to harmonize TMB measurement may bolster the potential clinical utility of TMB reporting.

Duration: 1 hr

Level of Instruction: Basic

This webinar is part 2 of a two-part series exploring the role of TMB testing in relationship to other tumor biomarkers as well as the standardization of TMB testing.


This program has been supported through an educational grant from Bristol-Myers Squibb.


AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Free for all)

SAM 1.0

Purchase Webinar + SAM

(Free for all)

Continuing Education Credit must be purchased and claimed by December 31, 2021

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 

Course Information
Course Date:
August 15, 2019
Course Objectives
  • Discuss the current state of TMB calculation and reporting as well as efforts to standardize this process across laboratories.
  • Understand the potential clinical utility of TMB and how it should be interpreted, especially in the context of other immunotherapy biomarkers.
  • Harness available information to improve implementation of molecularly targeted cancer diagnostics and therapies in the clinical setting.
Pre-Test for Making TMB Relevant in the Clinic: Best Practices for TMB Calculation, Reporting, and Interpretation (CE Available)
Making TMB Relevant in the Clinic: Best Practices for TMB Calculation, Reporting, and Interpretation (CE Available)
Post-Test for Making TMB Relevant in the Clinic: Best Practices for TMB Calculation, Reporting, and Interpretation (CE Available)
Individual topic purchase: Selected
Products
Stenzinger Presentation Only
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00